Advocacy at a Glance STEVEN GROSSMAN 1/27/17 Advocacy at a Glance STEVEN GROSSMAN 1/27/17 Trump Era Begins at HHS and FDA and more Read More Analysis and Commentary STEVEN GROSSMAN 1/19/17 Analysis and Commentary STEVEN GROSSMAN 1/19/17 Will Next Monday Be Different Than Today? Read More Advocacy at a Glance STEVEN GROSSMAN 1/19/17 Advocacy at a Glance STEVEN GROSSMAN 1/19/17 Prepping for the New Congress: Macro- and Micro-Budget Considerations for FDA and more Read More Analysis and Commentary STEVEN GROSSMAN 1/13/17 Analysis and Commentary STEVEN GROSSMAN 1/13/17 Advocacy and the "Iron Triangle" of Deficit Reduction Read More Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Sequester May Follow April 28 Expiration of FY 17 CR Read More Analysis and Commentary STEVEN GROSSMAN 1/6/17 Analysis and Commentary STEVEN GROSSMAN 1/6/17 The Speedy Appointment of a New Commissioner? Read More Advocacy at a Glance STEVEN GROSSMAN 1/6/17 Advocacy at a Glance STEVEN GROSSMAN 1/6/17 Wishing Everyone a Happy and Healthy New Year. Read More Analysis and Commentary STEVEN GROSSMAN 12/16/16 Analysis and Commentary STEVEN GROSSMAN 12/16/16 Time for a Deep Breath Before the New Year Begins Read More Advocacy at a Glance STEVEN GROSSMAN 12/16/16 Advocacy at a Glance STEVEN GROSSMAN 12/16/16 FY 17 Continuing Resolution to Run Through April 28, 2017 Read More Analysis and Commentary STEVEN GROSSMAN 12/9/16 Analysis and Commentary STEVEN GROSSMAN 12/9/16 Setting the Advocacy Stage for FY 18 and After Read More Advocacy at a Glance STEVEN GROSSMAN 12/9/16 Advocacy at a Glance STEVEN GROSSMAN 12/9/16 Continuing Resolution Close, But May Not Make Friday Night Deadline Read More Analysis and Commentary STEVEN GROSSMAN 12/5/16 Analysis and Commentary STEVEN GROSSMAN 12/5/16 21st Century Cures Passes House -- with Pros and Cons Read More Advocacy at a Glance STEVEN GROSSMAN 12/5/16 Advocacy at a Glance STEVEN GROSSMAN 12/5/16 21st Century Cures Passes House; Set for Senate Vote Next Week Read More Analysis and Commentary STEVEN GROSSMAN 11/21/16 Analysis and Commentary STEVEN GROSSMAN 11/21/16 Significant Change Is Always Hard Read More Advocacy at a Glance STEVEN GROSSMAN 11/21/16 Advocacy at a Glance STEVEN GROSSMAN 11/21/16 Short-Term Continuing Resolution Likely Read More Analysis and Commentary STEVEN GROSSMAN 11/11/16 Analysis and Commentary STEVEN GROSSMAN 11/11/16 Ensuring and Advocating for an FDA that Works Read More Advocacy at a Glance STEVEN GROSSMAN 11/11/16 Advocacy at a Glance STEVEN GROSSMAN 11/11/16 Mr. Trump, the Election and FDA Read More Analysis and Commentary STEVEN GROSSMAN 11/7/16 Analysis and Commentary STEVEN GROSSMAN 11/7/16 Alliance Has No Prognosis for the Lame Duck Read More Advocacy at a Glance STEVEN GROSSMAN 11/7/16 Advocacy at a Glance STEVEN GROSSMAN 11/7/16 FDA and the Elections: Many Unknowns Read More Analysis and Commentary STEVEN GROSSMAN 10/28/16 Analysis and Commentary STEVEN GROSSMAN 10/28/16 Musical Chairs and Post-Election Congressional Committee Leadership Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 1/27/17 Advocacy at a Glance STEVEN GROSSMAN 1/27/17 Trump Era Begins at HHS and FDA and more Read More
Analysis and Commentary STEVEN GROSSMAN 1/19/17 Analysis and Commentary STEVEN GROSSMAN 1/19/17 Will Next Monday Be Different Than Today? Read More
Advocacy at a Glance STEVEN GROSSMAN 1/19/17 Advocacy at a Glance STEVEN GROSSMAN 1/19/17 Prepping for the New Congress: Macro- and Micro-Budget Considerations for FDA and more Read More
Analysis and Commentary STEVEN GROSSMAN 1/13/17 Analysis and Commentary STEVEN GROSSMAN 1/13/17 Advocacy and the "Iron Triangle" of Deficit Reduction Read More
Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Sequester May Follow April 28 Expiration of FY 17 CR Read More
Analysis and Commentary STEVEN GROSSMAN 1/6/17 Analysis and Commentary STEVEN GROSSMAN 1/6/17 The Speedy Appointment of a New Commissioner? Read More
Advocacy at a Glance STEVEN GROSSMAN 1/6/17 Advocacy at a Glance STEVEN GROSSMAN 1/6/17 Wishing Everyone a Happy and Healthy New Year. Read More
Analysis and Commentary STEVEN GROSSMAN 12/16/16 Analysis and Commentary STEVEN GROSSMAN 12/16/16 Time for a Deep Breath Before the New Year Begins Read More
Advocacy at a Glance STEVEN GROSSMAN 12/16/16 Advocacy at a Glance STEVEN GROSSMAN 12/16/16 FY 17 Continuing Resolution to Run Through April 28, 2017 Read More
Analysis and Commentary STEVEN GROSSMAN 12/9/16 Analysis and Commentary STEVEN GROSSMAN 12/9/16 Setting the Advocacy Stage for FY 18 and After Read More
Advocacy at a Glance STEVEN GROSSMAN 12/9/16 Advocacy at a Glance STEVEN GROSSMAN 12/9/16 Continuing Resolution Close, But May Not Make Friday Night Deadline Read More
Analysis and Commentary STEVEN GROSSMAN 12/5/16 Analysis and Commentary STEVEN GROSSMAN 12/5/16 21st Century Cures Passes House -- with Pros and Cons Read More
Advocacy at a Glance STEVEN GROSSMAN 12/5/16 Advocacy at a Glance STEVEN GROSSMAN 12/5/16 21st Century Cures Passes House; Set for Senate Vote Next Week Read More
Analysis and Commentary STEVEN GROSSMAN 11/21/16 Analysis and Commentary STEVEN GROSSMAN 11/21/16 Significant Change Is Always Hard Read More
Advocacy at a Glance STEVEN GROSSMAN 11/21/16 Advocacy at a Glance STEVEN GROSSMAN 11/21/16 Short-Term Continuing Resolution Likely Read More
Analysis and Commentary STEVEN GROSSMAN 11/11/16 Analysis and Commentary STEVEN GROSSMAN 11/11/16 Ensuring and Advocating for an FDA that Works Read More
Advocacy at a Glance STEVEN GROSSMAN 11/11/16 Advocacy at a Glance STEVEN GROSSMAN 11/11/16 Mr. Trump, the Election and FDA Read More
Analysis and Commentary STEVEN GROSSMAN 11/7/16 Analysis and Commentary STEVEN GROSSMAN 11/7/16 Alliance Has No Prognosis for the Lame Duck Read More
Advocacy at a Glance STEVEN GROSSMAN 11/7/16 Advocacy at a Glance STEVEN GROSSMAN 11/7/16 FDA and the Elections: Many Unknowns Read More
Analysis and Commentary STEVEN GROSSMAN 10/28/16 Analysis and Commentary STEVEN GROSSMAN 10/28/16 Musical Chairs and Post-Election Congressional Committee Leadership Read More
